Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma

IntroductionThe programmed death-1 (PD-1) immune checkpoint inhibitor pembrolizumab is currently approved in the US for the first-line (1L) treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), either alone or in combination with platinum and 5-fluorouracil (5-FU)....

Celý popis

Podrobná bibliografie

Hlavní autoři:	Christopher M. Black, Dandan Zheng, Gleicy M. Hair, Lei Ai, Liya Wang, Daisuke Goto, Nati Lerman, Behzad Bidadi, Glenn J. Hanna
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-02-01
Edice:	Frontiers in Oncology
Témata:	head and neck squamous cell carcinoma antineoplastic agents PD-1 taxanes Kaplan-Meier estimate patient outcomes
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1348045/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!